BioCryst Pharmaceuticals, Inc. (BCRX) Profit Margins
Over the twelve months to 2026-06-30, BioCryst Pharmaceuticals, Inc. (BCRX) had operating margin -33.3%, net margin -40.9%, free cash flow margin 39.7%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
BCRXBioCryst Pharmaceuticals, Inc.Follow BCRX — free
—
Price chart with a free account
- Market cap
- 2.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | 100.0% | 97.2% | 91.3% | 95.5% | — | 92.4% | 91.3% | 95.4% | 97.6% | 98.6% | 97.3% | 97.8% | — | |
| Operating margin | -252.4% | -128.9% | -177.2% | -336.4% | -81.7% | -184.4% | -227.9% | -456.2% | -203.7% | -981.1% | -113.1% | -54.8% | -31.3% | -0.6% | 39.0% | -33.3% | |
| Net margin | -289.9% | -148.6% | -173.7% | -332.1% | -89.1% | -209.3% | -261.2% | -490.3% | -223.0% | -1026.4% | -117.1% | -91.2% | -68.4% | -19.7% | 30.2% | -40.9% | |
| FCF margin | -164.5% | -142.7% | -153.3% | -284.1% | -37.8% | -222.8% | -164.7% | -450.0% | -184.1% | -761.4% | -92.0% | -60.3% | -29.4% | -11.8% | 39.4% | 39.7% |
USD millions · SEC XBRL
BioCryst Pharmaceuticals, Inc. — questions
- What is BioCryst Pharmaceuticals, Inc.'s operating margin?
- -33.3% over the twelve months to 2026-06-30.
- What is BioCryst Pharmaceuticals, Inc.'s net profit margin?
- -40.9% over the twelve months to 2026-06-30.
Every figure on this page comes from BioCryst Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.